Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: no significant difference between present and historical results.
Eighty-four patients were treated early with nimodipine intravenously, and thereafter orally, up to 21 days after aneurysmal subarachnoid hemorrhage. Thirty-nine patients in the nimodipine-treated group were carefully selected to be compared with similar patients from a historical control group (114 patients) conventionally treated. The causes of poor results were clinically identified as follows: delayed ischemic deterioration (DID), rebleeding, complications of surgery, or not defined. There was no significant difference in the distribution of DID or outcome at follow-up examination (at least 6 months later) between the nimodipine-treated group and the control group.